Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBiocon

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Biocon can touch Rs 286: Vayalar

      Manoj Murlidharan Vayalar, IIFL is of the view that Biocon can touch Rs 286.

    • 6 stock ideas to liven up your trade

      On CNBC-TV18's show Super Six, market gurus Manas Jaiswal, manasjaiswal.com, Rajeev Agarwal, dynamixresearch.in and Vikrant Jadeja, vibranttrades.com, place their bets on two stocks each, thus offering investors a variety of options to choose from.

    • KYI: Expert tells you which stocks to trade next week

      Weak corporate earnings pushed stock market into the red for the seventh session in a row. Indices ended at their lowest level so far this year the Nifty slipped 35 points, Sensex dropped 95 points on Friday.

    • Short Biocon, says Sukhani

      Short Biocon, says Sudarshan Sukhani of s2analytics.com. It has completed its bull market and now it has made a fairly bearish pattern and this bearish pattern will breakdown.

    • Super Six stocks you can bet on Jan 08

      On CNBC-TV18's show Super Six, market gurus Manav Chopra of Nirmal Bang, Rajesh Jain of Religare Sec and Rakesh Gandhi of FRR shares, place their bets on two stocks each, thus offering investors a variety of options to choose from.

    • Top super six stocks ideas for December 18

      On CNBC-TV18's show Super Six, market gurus Vikrant Jadeja of Vibranttrades.com, Shardul Kulkarni of Angel Broking and Rajesh Jain of Religare Sec, place their bets on two stocks each, thus offering investors a variety of options to choose from.

    • See upside in Biocon, says Sudarshan Sukhani

      See upside in Biocon, says Sudarshan Sukhani of s2analytics.com. It has done the right things from Rs 200 to Rs 300. Then it went through a small correction and that correction seems to be getting over.

    • Vayalar upbeat on JP Associates, GMR Infra, Biocon

      Manoj Murlidharan Vayalar, IIFL PReMIA is upbeat on JP Associates, GMR Infra and Biocon and expects stocks are likely to see good upmove.

    • Buy Dr Reddy's; Divis Lab, Biocon good bets: IIFL Cap

      Concentrating on the pharma space, Bino Pathiparampil of IIFL Capital told CNBC-TV18 the success of Biocon‘s oral insulin product deal would be a positive for the company. He also has a buy on Dr Reddy‘s and believes it should give a 25 percent plus upside in the next one year.

    • Tulsian recommends Radico Khaitan, KFA, HDIL

      In an interview to CNBC-TV18, SP Tulsian of sptulsian.com tells he is positive on most Mumbai-based realty stocks. He says he has a positive stance on HDIL, DB Realty, Ajmera, Orbit Corporation.

    • Short Biocon, says Sudarshan Sukhani

      Short Biocon, says Sudarshan Sukhani of s2analytics.com.

    • Sell Biocon, says Sudarshan Sukhani

      Sell Biocon, says Sudarshan Sukhani of s2analytics.com. We have seen a bearish head and shoulder pattern, getting confirmed, which tells us that it‘s not just a small correction probably a steep correction is in the offing. So for a short-term trader a steep correction is a good opportunity to take money on the short side.

    • Buy Biocon, Tata Motors DVR, Mphasis: Merani

      In CNBC-TV18's popular show Bull's Eye, Nooresh Merani, AMSEC Research shares trading strategy of the day.

    • Biocon to outperform: Sudarshan Sukhani

      Biocon is likely to outperform, says Sudarshan Sukhani of s2analytics.com. It has been an excellent stock and willing to make new highs again.

    • Bull's eye: Buy Sonata Soft, NDTV, Jindal Poly, MphasiS

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • Super Six stocks you can bet on Sept 10

      On CNBC-TV18's show Super Six, market gurus Manas Jaiswal of manasjaiswal.com, Sanjeev Agarwal of Dynamix Research & Capital Management and Manav Chopra of Nirmal Bang, place their bets on two stocks each, thus offering investors a variety of options to choose from.

    • Buy Biocon, says Sudarshan Sukhani

      Buy Biocon, says Sudarshan Sukhani of s2analytics.com. The stock went down, corrected, made a base and rallied. This is exactly what a good stock should do. It continues the rally.

    • Buy Bharti Airtel, says Sudarshan Sukhani

      Buy Bharti Airtel, says Sudarshan Sukhani of s2analytics.com.

    • 6 trading stocks for short term gain

      On CNBC-TV18's show Super Six, market gurus Vishal Kshatriya of Edelweiss, Arunesh Madan of Augment Investment and Rakesh Gandhi of LKP, place their bets on two stocks each, thus offering investors a variety of options to choose from.

    • Biocon may add 30-40%, says Mohindar

      Rahul Mohindar of viratechindia.com expects 30-40% rally in Biocon, as over the last one or two weeks the stock has been strong and looking good from an investment angle.

    • Buy Biocon, says Amit Gupta

      Buy Biocon, says Amit Gupta of ICICI Direct. If somebody is buying the stock then can look for a target of Rs 265. On the downside the immediate support lies around Rs 238 for the stock.

    • CESC has target of Rs 360-370: Sudarshan Sukhani

      CESC has target of Rs 360-370, says Sudarshan Sukhani of s2analytics.com. It is now a buying opportunity for day traders and anyone wanting to take a position should get a little easy, take a stoploss and expect Rs 350-360 on it.

    • Buy Biocon, says Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Biocon. It has completed a bear market and rallied from Rs 190-200 and that rally seems to be consistent. It is already 20% up and anything that is 20% up deserves attention.

    • Biocon has target of Rs 260: Sukhani

      Biocon has target of Rs 260, says Sudarshan Sukhani of s2analytics.com.

    • Super Six short term picks for July 24

      On CNBC-TV18's show Super Six, market gurus Manas Jaiswal, Technical Analyst at manasjaiswal.com, Rajesh Jain, EVP Retail Research at Religare Sec and Rakesh Gandhi, Sr Technical Analyst at LKP, place their bets on two stocks each, thus offering investors a variety of options to choose from.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347